Analysts and industry observers report a marked commercial slowdown for gene therapies as pricing levels in the millions and lower-than-expected patient uptake squeeze market prospects. Firms are confronting payer scrutiny, tougher regulatory interactions, and slower fundraising, prompting some companies to pause or reprioritize programs. The retrenchment raises questions about sustainable pricing models and the long‑term commercial pathway for one‑time curative therapies; investors and developers will watch reimbursement pilots and value‑based contracting pilots closely.